AIM: To investigate the serum positive percentage of TT virus (TTV) in patients with chronic hepatitis B or C and the response of the coinfected TTV to interferon (IFN) during IFN therapy for chronic hepatitis B and C. METHODS: We retrospectively studied the serum samples of 70 patients with chronic hepatitis who had received IFN-alpha therapy from January 1997 to June 2000, which included 40 cases of hepatitis B and 30 hepatitis C. All the patients had been followed up for at least 6 months after the end of IFN therapy. The serum TTV DNA was detected using the polymerase chain reaction (PCR) before and every month during the course of IFN treatment. RESULTS: TTV infection was detected in 15% (6/40) of the chronic hepatitis B group and 30% (9/30) of the chronic hepatitis C group. Loss of serum TTV DNA during IFN therapy occurred in 3 of 6 patients (50%) and 6 of 9 (67%) of hepatitis B and C groups, respectively. Seronegativity of TTV was found all during the first month of IFN therapy in the 9 patients. There was no correlation between the seroconversion of TTV and the biochemical changes of the patients. CONCLUSION: TTV is not infrequently coinfected in patients with chronic hepatitis B and C in Taiwan, and more than half of the TTV infections are IFN-sensitive. However, the loss of serum TTV DNA does not affect the clinical course of the patients with chronic hepatitis B or C.
AIM: To investigate the serum positive percentage of TT virus (TTV) in patients with chronic hepatitis B or C and the response of the coinfected TTV to interferon (IFN) during IFN therapy for chronic hepatitis B and C. METHODS: We retrospectively studied the serum samples of 70 patients with chronic hepatitis who had received IFN-alpha therapy from January 1997 to June 2000, which included 40 cases of hepatitis B and 30 hepatitis C. All the patients had been followed up for at least 6 months after the end of IFN therapy. The serum TTV DNA was detected using the polymerase chain reaction (PCR) before and every month during the course of IFN treatment. RESULTS:TTVinfection was detected in 15% (6/40) of the chronic hepatitis B group and 30% (9/30) of the chronic hepatitis C group. Loss of serum TTV DNA during IFN therapy occurred in 3 of 6 patients (50%) and 6 of 9 (67%) of hepatitis B and C groups, respectively. Seronegativity of TTV was found all during the first month of IFN therapy in the 9 patients. There was no correlation between the seroconversion of TTV and the biochemical changes of the patients. CONCLUSION:TTV is not infrequently coinfected in patients with chronic hepatitis B and C in Taiwan, and more than half of the TTV infections are IFN-sensitive. However, the loss of serum TTV DNA does not affect the clinical course of the patients with chronic hepatitis B or C.
Authors: Y Poovorawan; A Theamboonlers; P Jantaradsamee; N Kaew-in; P Hirsch; P Tangkitvanich Journal: Infection Date: 1998 Nov-Dec Impact factor: 3.553
Authors: K Chayama; M Kobayashi; A Tsubota; M Kobayashi; Y Arase; Y Suzuki; S Saitoh; N Murashima; K Ikeda; K Okamoto; M Hashimoto; M Matsuda; H Koike; M Kobayashi; H Kumada Journal: J Gen Virol Date: 1999-03 Impact factor: 3.891
Authors: Y Akahane; M Sakamoto; Y Miyazaki; S Okada; T Inoue; M Ukita; H Okamoto; Y Miyakawa; M Mayumi Journal: J Med Virol Date: 1999-07 Impact factor: 2.327
Authors: D S Chen; G C Kuo; J L Sung; M Y Lai; J C Sheu; P J Chen; P M Yang; H M Hsu; M H Chang; C J Chen Journal: J Infect Dis Date: 1990-10 Impact factor: 5.226
Authors: S Utsunomiya; K Yoshioka; T Wakita; H Seno; K Takagi; M Ishigami; M Yano; K Watanabe; M Kobayashi; K Watanabe; H Kishimoto; S Kakumu Journal: Am J Gastroenterol Date: 1999-12 Impact factor: 10.864
Authors: P Pontisso; M G Ruvoletto; G Fattovich; L Chemello; A Gallorini; A Ruol; A Alberti Journal: Gastroenterology Date: 1993-11 Impact factor: 22.682
Authors: T Poynard; P Bedossa; M Chevallier; P Mathurin; C Lemonnier; C Trepo; P Couzigou; J L Payen; M Sajus; J M Costa Journal: N Engl J Med Date: 1995-06-01 Impact factor: 91.245
Authors: Javier Moreno; Gloria Moraleda; Rafael Barcena; Mluisa Mateos; Santos del Campo Journal: World J Gastroenterol Date: 2004-01 Impact factor: 5.742
Authors: Maha A Al-Mozaini; Mohammed N Al-Ahdal; George Kessie; Damian M Dela Cruz; Mohammed A Rezeig; Fahad J Al-Shammary Journal: Ann Saudi Med Date: 2006 Nov-Dec Impact factor: 1.526
Authors: Carsten T Herz; Oana C Kulterer; Dorian Kulifaj; Fanny Gelas; Bernhard Franzke; Frederik Haupenthal; Gerhard Prager; Felix B Langer; Rodrig Marculescu; Alexander R Haug; Florian W Kiefer; Gregor Bond Journal: Front Endocrinol (Lausanne) Date: 2022-09-28 Impact factor: 6.055